key: cord-1026240-dnkxb6ax
authors: Paterson, Ian; Ramanathan, Krishnan; Aurora, Rakesh; Bewick, David; Chow, Chi-Ming; Clarke, Brian; Cowan, Simone; Ducharme, Anique; Gin, Kenneth; Graham, Michelle; Gupta, Anil; Jassal, Davinder S.; Kazmi, Mustapha; Krahn, Andrew; Lamarche, Yoan; Marelli, Ariane; Roifman, Idan; Ruel, Marc; Singh, Gurmeet; Sterns, Larry; Turgeon, Ricky; Virani, Sean; Wong, Kenny K.; Zieroth, Shelley
title: Long COVID-19: A Primer for Cardiovascular Health Professionals On Behalf of the CCS Rapid Response Team
date: 2021-06-06
journal: Can J Cardiol
DOI: 10.1016/j.cjca.2021.05.011
sha: 96fb1457296225158d0354d67c08e318c4757d2c
doc_id: 1026240
cord_uid: dnkxb6ax

It is now widely recognized that COVID-19 illness can be associated with significant intermediate and potentially longer-term physical limitations. The term “Long COVID-19” is used to define any patient with persistent symptoms after acute COVID-19 (i.e. after 4 weeks). It is postulated that cardiac injury may be linked to symptoms that persist following resolution of acute infection, as part of this syndrome. The Canadian Cardiovascular Society Rapid Response Team has generated this document to provide guidance to health care providers on the optimal management of patients with suspected cardiac complications of Long COVID-19.

Approximately 20-30% of patients infected with severe acute respiratory syndrome coronavirus-2 have symptoms persisting beyond their initial illness, so called Long COVID-19. The Canadian Cardiovascular Society Rapid Response Team has developed a practical guide to health care practitioners in the management of potential cardiovascular issues arising in these cases.

It is now widely recognized that COVID-19 illness can be associated with significant intermediate and potentially longer-term physical limitations. The term "Long COVID-19" is used to define any patient with persistent symptoms after acute COVID-19 (i.e. after 4 weeks). It is postulated that cardiac injury may be linked to symptoms that persist following resolution of acute infection, as part of this syndrome. The Canadian Cardiovascular Society Rapid Response Team has generated this document to provide guidance to health care providers on the optimal management of patients with suspected cardiac complications of Long COVID-19.

An estimated 870,000 Canadians have been infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) as of March 2, 2021, including over 22,000 known deaths. Cardiac injury, defined as an elevation in serum troponin, has been documented in up to 45% of inpatients with COVID-19 1 and has been linked to worse outcomes 2 . It is also postulated that this type of injury may be linked to symptoms that persist following resolution of acute infection, as part of the syndrome commonly referred to as "Long COVID-19". The purpose of this document is to provide guidance to health care providers on the optimal management of patients with suspected cardiac complications of Long COVID-19. It must be recognized that this is an evolving area with little data at present to guide management.

Several potential mechanisms for myocardial injury secondary to SARS-CoV-2 infection have been proposed, including: i) myocarditis from either direct viral toxicity and/or bystander immune damage; ii) myocardial ischemia from microvascular thrombosis; and/or iii) COVID-19 related hypoxemia. More recently, histopathological data from 201 COVID-19 patients undergoing endomyocardial biopsy (N=9) or autopsy (N=192) suggests that myocarditis is present in only 4.5%, despite a high likelihood of referral bias 3 . However, it is unclear if any of these cardiac manifestations during acute COVID-19 leads to significant long-term consequences.

Small cohort studies utilizing cardiac MRI have reported conflicting results 4,5 , further highlighting the need to better elucidate potential long-term cardiac sequelae of COVID-19, especially as it pertains to patient symptoms and functional impairments. Furthermore, no data presently exist to support or refute the cardiovascular impact of COVID-19 in patients with or without pre-existing cardiac conditions.

It is now widely recognized that COVID-19 illness can be associated with significant intermediate and potentially longer-term physical limitations. Recent survey data from the Office for National Statistics in the United Kingdom found that 21% of respondents with COVID-19 exhibit symptoms for longer than 5 weeks and 10% exhibit symptoms for greater than 12 weeks. While definitions are evolving, the term Long COVID-19 is commonly used to define any patient with persistent symptoms after acute COVID-19 (i.e. after 4 weeks) (Supplementary Table S1 ).

There is a lack of high-quality data on the prevalence of symptom subtypes in patients with Long COVID-19. A review of evidence performed by the National Institute for Health and Care Excellence in the UK found that fatigue and shortness of breath are commonly reported, affecting up to 98% and 85% of patients respectively, amongst other multisystem symptoms.

Chest pain or palpitations have been reported in 10-44% of cases and are potentially more common at 4-12 weeks post COVID-19 infection.

A growing awareness of the long-term impact of COVID-19 infections has led to the formation of patient-initiated online support groups, government-sponsored information websites for patients (e,g, www.yourcovidrecovery.nhs.uk) and more recently, ambulatory clinics specializing in the care of these patients. Generally, cardiac specialists have either been integrated into these clinics or have provided consultation on an ad hoc basis. Thus, the following recommendations are largely based on expert opinion and the current collective experience.

Patients with diagnosed COVID-19 illness > 4 weeks ago and:

(1) Persistent or new unexplained chest pain. A cardiac etiology is more likely with multiple cardiac risk factors, documented cardiac injury and/or new Q waves or ST-T wave abnormalities on ECG, during or after initial COVID-19 illness.

(2) Shortness of breath. A cardiac etiology is more likely with elevated BNP, left ventricular dysfunction on imaging and/or radiographic evidence of pulmonary edema.

(3) Frequent palpitations. A cardiac etiology is more likely if associated with pre-syncope or syncope and/or a significant arrhythmia is detected on Holter or other cardiac monitoring device. For patients with persistent sinus tachycardia, consider a cardiac etiology in the absence of systemic causes (e.g. fever, anemia, and hypoxia).

(4) Postural light headedness. A cardiovascular etiology is more likely if orthostatic hypotension is documented.

The Canadian Cardiovascular Society Rapid Response Team has placed an emphasis on physical examination and non-invasive assessment utilising local expertise and periodic surveillance, especially amongst those with pre-existing cardiac conditions or multi-system disease. (Table 1 )

Although there are no specific recommendations for managing cardiac symptoms in Long COVID-19 patients, there is considerable support for maintaining guideline-based goal-directed therapy in patients with pre-existing cardiovascular disease. Patients with new cardiac findings or symptoms should be managed using contemporary treatments, similar to patients without a history of COVID-19 infection. (Supplementary Table S2 )

After careful investigations to identify and treat cardiac and/or pulmonary causes of patient symptoms, many may remain symptomatic with chronic fatigue and tiredness. Although in some individuals these symptoms may be attributed to the slow nature of their recovery following a critical illness, in others it may result from deconditioning and other unrecognised factors. There is no clear relationship between chronicity of symptoms and severity of initial COVID-19 illness. Long COVID-19 patients often report less energy than pre-illness, and everyday situations requiring physical, cognitive, and/or emotional stamina may be exhausting in a waxing and waning pattern.

In many patients, a tailored return to exercise can be a useful adjunctive therapy. This requires a multi-disciplinary team rehabilitation service consisting of nurses, physiotherapists, physiatrists, exercise specialists, neurologists, psychiatrists, respirologists, rehabilitation experts and cardiologists to co-ordinate an individualised plan including in-person and electronic supports. Additional considerations should include baseline health, premorbid function, biomechanical assessments, exercise prescription and a holistic patient review; much of which could be delivered by telemedicine. The Long COVID-19 patient care map illustrated in Figure 1 enables a cycle of "learn-teach and modify" to further refine interventions.

Return to exercise is often regarded as an important milestone of recovering from COVID-19, resulting in post exertional malaise. Many with this syndrome experience a cycle of "push and crash." (Supplementary Figure S1) The symptoms of post exertional malaise resemble myalgic encephalitis or chronic fatigue syndrome, and typically occur 24-72h post trigger, potentially lasting for several days. The opposite of "push and crash" is pacing. This further emphasizes the importance of early involvement of a multidisciplinary approach to prevent and support "push and crash" candidates to a path of pacing with reduced suffering, and improved sense of control and well-being.

Finding the individual's envelope-paying attention to the level of triggers, which may be physical, emotional or cognitive

The individual adapting to their envelope-learning to control triggers Expanding their envelope-gradual progression and adaptation

The management strategies proposed above for Long COVID- 19 have not yet been evaluated in clinical trials. However, these recommendations appear reasonable given current knowledge and experience. Future work on COVID-19 should continue to assess knowledge gaps and evaluate the long-term cardiovascular effects and potential impact on patient wellness and survival. Furthermore, long-term outcomes should also be studied in asymptomatic, recovered COVID-19 patients to determine any potential links to latent cardiovascular disease. 

Incidence of myocardial injury in COVID-19-infected patients: A systematic review and meta-analysis. Diseases

Cardiac injury is associated with severe outcome and death in patients with coronavirus disease 2019 (COVID-19) infection: A systematic review and metaanalysis of observational studies

Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week

Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19)

Patterns of myocardial injury in recovered troponinpositive COVID-19 patients assessed by cardiovascular magnetic resonance